Newsroom
Latest News
News
Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO
SALT LAKE CITY, May 15, 2023 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,…
News
Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2023 Financial Results on May 10, 2023
Salt Lake City, April 27, 2023 —Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and…
News
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS
SALT LAKE CITY, March 22, 2023 — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and…
News
Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2022 Financial Results on March 22, 2023
Salt Lake City, March 9, 2023 —Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,…
News
SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES
SALT LAKE CITY, UT – February 23, 2023 – Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information…
News
Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL
PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay SALT LAKE CITY, Feb. 15, 2023 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on…
News
FORS MARSH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH SERA PROGNOSTICS
Sera Prognostics and Fors Marsh are collaborating to provide Sera’s PreTRM® Test to employees at Fors Marsh as part of their maternity benefits, effective January 1, 2023.
News
SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA PREDICTING CLINICAL UTILITY AND COST EFFECTIVENESS OF THE PRETRM® TEST-AND-TREAT STRATEGY ACROSS DIVERSE POPULATIONS
Sera Prognostics Inc. announced the publication of results from a clinical utility and cost-effectiveness modeling study, ACCORDANT (Analyses aCross Congruent studies ReDucing Adverse pregNancy ouTcomes).
News
SERA PROGNOSTICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
SALT LAKE CITY, Nov. 9, 2022 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today…
News
Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2022 Financial Results on November 9
Sera Prognostics announced that it will report third quarter fiscal year 2022 financial results on Wednesday, November 9, 2022, after the close of the market.